|
|
|
|
Ideaya Biosciences Inc (IDYA) |
|
Price: $31.1700
$0.30 
0.972%
|
| Day's High:
| $31.7
| Week Perf:
| -1.36 %
|
| Day's Low: |
$ 30.74 |
30 Day Perf: |
21 % |
| Volume (M): |
543 |
52 Wk High: |
$ 32.37 |
| Volume (M$): |
$ 16,938 |
52 Wk Avg: |
$21.81 |
| Open: |
$30.74 |
52 Wk Low: |
$13.29 |
|
|
| Market Capitalization (Millions $) |
1,870 |
| Shares
Outstanding (Millions) |
60 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
23 |
| Net Income (TTM) (Millions $) |
-103 |
| Cash Flow (TTM) (Millions $) |
51 |
| Capital Exp. (TTM) (Millions $) |
2 |
Ideaya Biosciences Inc
Company Address: 7000 Shoreline Court South San Francisco 94080 CA
Company Phone Number: 443-6209 Stock Exchange / Ticker: NASDAQ IDYA
| IDYA is expected to report next financial results on March 06, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Evofem Biosciences Inc
For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.
|
|
Shuttle Pharmaceuticals Holdings Inc
In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.
|
|
Cingulate Inc
Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.
|
|
Harrow Inc
As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.
|
|
Renovorx Inc
As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.93 $ |
| Revenues (TTM) |
0.39 $
|
| Cash Flow (TTM) |
0.84 $ |
| Cash |
7.81 $
|
| Book Value |
8.47 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.93 $
|
| Revenues (TTM) |
0.39 $ |
| Cash Flow (TTM) |
0.84 $ |
| Cash |
7.81 $
|
| Book Value |
8.47 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
